Study of immunotherapy and regorafenib for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (regorafenib) for people with advanced hepatocellular carcinoma (liver cancer) that has gotten worse after or during first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have advanced liver cancer that cannot be surgically removed.
- Your cancer must have gotten worse during or after your first treatment, or you could not tolerate that treatment.
- You need at least one tumor that can be measured on a scan.
- You must have good liver function (Child-Pugh class A), good kidney and blood counts, and be able to walk and care for yourself (ECOG 0-1).
- If you have hepatitis B or C, it must be well-controlled with antiviral therapy.
- You cannot have had regorafenib before, or have certain other health problems (like serious heart disease, bleeding issues, or autoimmune diseases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This study tests two targeted therapy drugs, lenvatinib or regorafenib, for people with advanced liver cancer that got worse after first treatment with immunotherapy. It aims to see if these drugs can help when immunotherapy stops working.
This trial tests a new treatment called SH006 for advanced liver cancer that has not responded to previous immunotherapy. It compares SH006 to another drug, regorafenib, to see which works better.
This trial tests a new combination of drugs (iparomlimab, tuvonralimab, and lenvatinib) along with a procedure called TACE that delivers chemotherapy directly to the liver. It is for people with advanced hepatocellular carcinoma who have not had previous treatment or have had only one prior therapy.
This trial tests whether regorafenib, a targeted cancer drug, can help patients with advanced liver cancer whose disease progressed after or couldn't tolerate first-line immunotherapy. The goal is to see if this drug can slow or shrink the cancer.
This trial tests whether adding trastuzumab to the standard drug regorafenib works better than regorafenib alone for people with advanced liver cancer that has grown after initial treatment. It is for those who have already received a type of immunotherapy combined with a targeted drug (like atezolizumab + bevacizumab).
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.